StockNews.com assumed coverage on shares of Trinity Biotech (NASDAQ:TRIB – Get Free Report) in a research report issued on Friday. The firm set a “sell” rating on the stock.
Trinity Biotech Stock Performance
NASDAQ TRIB opened at $0.75 on Friday. The business has a fifty day moving average price of $0.65 and a 200 day moving average price of $0.91. The company has a market cap of $13.61 million, a P/E ratio of -0.33 and a beta of 0.86. Trinity Biotech has a one year low of $0.48 and a one year high of $3.55.
Institutional Trading of Trinity Biotech
An institutional investor recently raised its position in Trinity Biotech stock. Hunter Associates Investment Management LLC grew its stake in Trinity Biotech plc (NASDAQ:TRIB – Free Report) by 5.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 378,590 shares of the company’s stock after purchasing an additional 18,780 shares during the period. Hunter Associates Investment Management LLC’s holdings in Trinity Biotech were worth $334,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 78.97% of the company’s stock.
About Trinity Biotech
Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.
Read More
- Five stocks we like better than Trinity Biotech
- What is the Nasdaq? Complete Overview with History
- GlobalFoundries Stock Hits Bottom: Is a Rebound Coming?
- Are Penny Stocks a Good Fit for Your Portfolio?
- Here’s The Reason Goldman Sachs Is Bullish On MercadoLibre Stock
- Growth Investing: Should You Adopt This Investing Strategy in 2022?
- Analyst-Favorite Bitcoin Miner CleanSpark: Worth the Hype?
Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
